POST Online Media Lite Edition


Perrigo to buy Omega Pharma for $4.5 billion

Staff writer |
Perrigo Company plc and Omega Pharma NV have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for €3.6 billion, or $4.5 billion.

Article continues below

This includes the purchase of Omega's equity for €2.48 billion and the assumption of €1.1 billion in debt.

The transaction, funded through a combination of cash, debt, and equity, will enhance Perrigo's leading OTC product offering and expand its distribution through Omega's strong established platform.

Omega generated approximately $1.6 billion of revenue during the twelve months ended September 30, 2014, making it the fifth largest player within the European OTC market and the largest or second largest player in four individual European markets.

Omega owns many leading cough & cold, skincare, pain relief, weight management, and gastrointestinal treatment brands, among its portfolio of roughly 2,000 products. Omega has a strong presence in both established and emerging growth economies.

Including product acquisitions, Omega has delivered compound annual revenue growth of approximately 10% over the last five years. Headquartered in Belgium, Omega also offers geographic diversification with a commercial presence in 35 countries.

What to read next

Perrigo rejects Mylan's tender offer
Perrigo to sell Tysabri royalty stream in $2.85bn agreement
Mylan now says Perrigo is not a must...